JAMES T. DALTON, Ph.D., B.S.

Associate Professor
Pharmaceutical Sciences

Office: VAN VLEET CANCER CENTER
3 NORTH DUNLAP STREET
MEMPHIS TN 381630000
Tel: (901) 523-9700
jdalton@uthsc.edu

Publications

  1. Narayanan, R, Coss, CC, Yepuru, M, Kearbey, JD, Miller, DD, Dalton, JT. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol, 22 (11), 2448-65, 2008.
  2. Jones, A, Chen, J, Hwang, DJ, Miller, DD, Dalton, JT. Preclinical Characterization of a (S)-N-(4-Cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-Hydroxy-2-Methyl-Propanamide: A Selective Androgen Receptor Modulator for Hormonal Male Contraception. Endocrinology, 2008.
  3. Li, W, Hwang, DJ, Cremer, D, Joo, H, Kraka, E, Kim, J, Ross, CR, Nguyen, VQ, Dalton, JT, Miller, DD. Structure determination of chiral sulfoxide in diastereomeric bicalutamide derivatives. Chirality, 2008.
  4. Chen, J, Wang, Z, Lu, Y, Dalton, JT, Miller, DD, Li, W. Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma. Bioorg Med Chem Lett, 18 (11), 3183-7, 2008.
  5. Li, W, Lu, Y, Wang, Z, Dalton, JT, Miller, DD. Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. Bioorg Med Chem Lett, 17 (15), 4113-7, 2007.
  6. Li, W, Wang, Z, Gududuru, V, Zbytek, B, Slominski, AT, Dalton, JT, Miller, DD. Structure-activity relationship studies of arylthiazolidine amides as selective cytotoxic agents for melanoma. Anticancer Res, 27 (2), 883-8, 2007.
  7. Hwang, DJ, Yang, J, Xu, H, Rakov, IM, Mohler, ML, Dalton, JT, Miller, DD. Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer. Bioorg Med Chem, 14 (19), 6525-38, 2006.
  8. Korukonda, R, Guan, N, Dalton, JT, Liu, J, Donkor, IO. Synthesis, calpain inhibitory activity, and cytotoxicity of P2-substituted proline and thiaproline peptidyl aldehydes and peptidyl alpha-ketoamides. J Med Chem, 49 (17), 5282-90, 2006.
  9. Nair, VA, Mustafa, SM, Mohler, ML, Dalton, JT, Miller, DD. Synthesis of oxazolidinedione derived bicalutamide analogs. Tetrahedron Lett, 47 (23), 3953-3955, 2006.
  10. Patil, R, Li, W, Ross, CR, Kraka, E, Cremer, D, Mohler, ML, Dalton, JT, Miller, DD. Cesium fluoride and tetra-n-butylammonium fluoride mediated 1,4-N-->O shift of disubstituted phenyl ring of a bicalutamide derivative. Tetrahedron Lett, 47 (23), 3941-3944, 2006.
  11. Segal, S, Narayanan, R, Dalton, JT. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opin Investig Drugs, 15 (4), 377-87, 2006.
  12. Gududuru, V, Hurh, E, Sullivan, J, Dalton, JT, Miller, DD. SAR studies of 2-arylthiazolidine-4-carboxylic acid amides: a novel class of cytotoxic agents for prostate cancer. Bioorg Med Chem Lett, 15 (18), 4010-3, 2005.
  13. Nair, VA, Mustafa, SM, Mohler, ML, Yang, J, Kirkovsky, LI, Dalton, JT, Miller, DD. Synthesis of irreversibly binding bicalutamide analogs for imaging studies. Tetrahedron Lett, 46 (28), 4821-4823, 2005.
  14. Gududuru, V, Hurh, E, Dalton, JT, Miller, DD. Discovery of 2-arylthiazolidine-4-carboxylic acid amides as a new class of cytotoxic agents for prostate cancer. J Med Chem, 48 (7), 2584-8, 2005.
  15. Nair, VA, Mustafa, SM, Mohler, ML, Fisher, SJ, Dalton, JT, Miller, DD. Synthesis of novel iodo derived bicalutamide analogs. Tetrahedron Lett, 45 (51), 9475-9477, 2004.
  16. Gududuru, V, Hurh, E, Dalton, JT, Miller, DD. Synthesis and antiproliferative activity of 2-aryl-4-oxo-thiazolidin-3-yl-amides for prostate cancer. Bioorg Med Chem Lett, 14 (21), 5289-93, 2004.
  17. Gududuru, V, Hurh, E, Durgam, GG, Hong, SS, Sardar, VM, Xu, H, Dalton, JT, Miller, DD. Synthesis and biological evaluation of novel cytotoxic phospholipids for prostate cancer. Bioorg Med Chem Lett, 14 (19), 4919-23, 2004.
  18. Marhefka, CA, Gao, W, Chung, K, Kim, J, He, Y, Yin, D, Bohl, C, Dalton, JT, Miller, DD. Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J Med Chem, 47 (4), 993-8, 2004.
  19. Yates, CR, Chang, C, Kearbey, JD, Yasuda, K, Schuetz, EG, Miller, DD, Dalton, JT, Swaan, PW. Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res, 20 (11), 1794-803, 2003.
  20. He, Y, Yin, D, Perera, M, Kirkovsky, L, Stourman, N, Li, W, Dalton, JT, Miller, DD. Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. Eur J Med Chem, 37 (8), 619-34, 2002.
  21. Rogers, TD, Gades, NM, Kearby, JD, Virgous, CK, Dalton, JT. Chronic restraint via tail immobilization of mice: effects on corticosterone levels and other physiologic indices of stress. Contemp Top Lab Anim Sci, 41 (1), 46-50, 2002.
  22. Zhu, Z, Becklin, RR, Desiderio, DM, Dalton, JT. Mass spectrometric characterization of the human androgen receptor ligand-binding domain expressed in Escherichia coli. Biochemistry, 40 (36), 10756-63, 2001.
  23. Marhefka, CA, Moore, BM, Bishop, TC, Kirkovsky, L, Mukherjee, A, Dalton, JT, Miller, DD. Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. J Med Chem, 44 (11), 1729-40, 2001.
  24. Yates, CR, Vysokanov, A, Mukherjee, A, Ludden, TM, Tolley, E, Meduri, GU, Dalton, JT. Time-variant increase in methylprednisolone clearance in patients with acute respiratory distress syndrome: a population pharmacokinetic study. J Clin Pharmacol, 41 (4), 415-24, 2001.
  25. Lan, LB, Dalton, JT, Schuetz, EG. Mdr1 limits CYP3A metabolism in vivo. Mol Pharmacol, 58 (4), 863-9, 2000.
  26. Zhou, D, Lu, Y, Steiner, MS, Dalton, JT. Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. Antimicrob Agents Chemother, 44 (10), 2659-63, 2000.
  27. Brimer, C, Dalton, JT, Zhu, Z, Schuetz, J, Yasuda, K, Vanin, E, Relling, MV, Lu, Y, Schuetz, EG. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein. Pharm Res, 17 (7), 803-10, 2000.
  28. Kirkovsky, L, Mukherjee, A, Yin, D, Dalton, JT, Miller, DD. Chiral nonsteroidal affinity ligands for the androgen receptor. 1. Bicalutamide analogues bearing electrophilic groups in the B aromatic ring. J Med Chem, 43 (4), 581-90, 2000.
  29. Mukherjee, A, Kirkovsky, LI, Kimura, Y, Marvel, MM, Miller, DD, Dalton, JT. Affinity labeling of the androgen receptor with nonsteroidal chemoaffinity ligands. Biochem Pharmacol, 58 (8), 1259-67, 1999.
  30. Hovinga, CA, Chicella, MF, Rose, DF, Eades, SK, Dalton, JT, Phelps, SJ. Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. Ann Pharmacother, 33 (5), 579-84, 1999.
  31. Dalton, JT, Meyer, MC, Golub, AL. Pharmacokinetics of aminolevulinic acid after oral and intravenous administration in dogs. Drug Metab Dispos, 27 (4), 432-5, 1999.
  32. Dalton, JT, Zhou, D, Mukherjee, A, Young, D, Tolley, EA, Golub, AL, Meyer, MC. Pharmacokinetics of aminolevulinic acid after intravesical administration to dogs. Pharm Res, 16 (2), 288-95, 1999.
  33. Dalton, JT, Mukherjee, A, Zhu, Z, Kirkovsky, L, Miller, DD. Discovery of nonsteroidal androgens. Biochem Biophys Res Commun, 244 (1), 1-4, 1998.
  34. Zhang, X, De Los Angeles, JE, He, MY, Dalton, JT, Shams, G, Lei, L, Patil, PN, Feller, DR, Miller, DD, Hsu, FL. Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potential binding interactions with alpha 2-adrenoceptors involving a "methyl pocket". J Med Chem, 40 (19), 3014-24, 1997.
  35. Hughes, TA, Heimberg, M, Wang, X, Wilcox, H, Hughes, SM, Tolley, EA, Desiderio, DM, Dalton, JT. Comparative lipoprotein metabolism of myristate, palmitate, and stearate in normolipidemic men. Metabolism, 45 (9), 1108-18, 1996.
  36. Mukherjee, A, Kirkovsky, L, Yao, XT, Yates, RC, Miller, DD, Dalton, JT. Enantioselective binding of Casodex to the androgen receptor. Xenobiotica, 26 (2), 117-22, 1996.
  37. Han, G, Israel, M, Seshadri, R, Dalton, JT, Sweatman, TW. Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat. Cancer Chemother Pharmacol, 37 (5), 472-8, 1996.
  38. Dalton, JT, Weintjes, MG, Au, JL. Effects of bladder resorption on pharmacokinetic data analysis. J Pharmacokinet Biopharm, 22 (3), 183-205, 1994.